[Recommendations] Creating Pull Incentives for Antimicrobials (March 24, 2021)
date : 3/24/2021
Tags: AMR
![[Recommendations] Creating Pull Incentives for Antimicrobials (March 24, 2021)](https://hgpi.org/en/wp-content/uploads/sites/2/PullIncentiveReccomendation-top_EN.jpg)
Since 2016, Health and Global Policy Institute has been working on the important issue of antimicrobial resistance through its work as secretariat of AMR Alliance Japan. Related to that work, today, the Nikkei FT Communicable Diseases Conference Asia Africa Medical Innovation Consortium (AMIC) AMR Consortium (Secretariat: AMR Alliance Japan) has announced new recommendation on the creation of a pull incentive for antimicrobials in Japan.
As we use antimicrobials more and more, the microorganisms that cause infectious diseases adapt, and grow resistant to treatment. This naturally occurring process is called “antimicrobial resistance” (AMR). The threat of AMR as a ‘silent pandemic’ is growing. In 2019, it was estimated that already approximately 8,000 deaths are occurring annually in Japan due to blood-stream infections attributable to two antimicrobial-resistant organisms, methicillin-resistant Staphylococcus aureus (MRSA) and fluoroquinolone-resistant Escherichia coli (E. coli). Antimicrobial Resistance (AMR) is already a health crisis. New antimicrobials are urgently needed to protect the public from this problem.
However, the number of new antimicrobials in development has been declining worldwide since the 1980s. This problem has arisen from a market failure. It can take 10-15 years and over US$1 billion to develop an antimicrobial. New antimicrobials are needed as insurance against the spread of AMR. For that reason, once an antimicrobial is approved for use, it is important to take care not to overuse it. As a result, new antimicrobials typically see low usage, and hence low sales, and companies face problems in covering post-approval costs. This issue has led to the collapse of five companies that developed antimicrobials in recent years.
The sustainable development of new antimicrobials will be impossible unless new policies are implemented to help address the problems in the antimicrobials market. Specifically, the world needs policies that can delink reimbursements for antimicrobials from their sales volume. Such measures are called “pull incentives.” Many countries are currently considering the implementation of these kinds of incentives. The United Kingdom has already begun a pull incentives pilot, and the United States is considering the Pasteur Act, which would create a pull incentive there as well.
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) has been serving as secretariat for the Nikkei FT Communicable Diseases Conference Asia Africa Asia Medical Innovation Consortium (AMIC) AMR Consortium. Over the course of FY2020, the AMR Consortium has developed recommendations on measures to solve the above issues and organize discussion toward the development of recommendations on the introduction of a pull incentive in Japan. The full recommendations are available in Japanese. An executive summary from the recommendations is available below.
Top Research & Recommendations Posts
- [Policy Recommendation] Preparing for “Disaster-Level Heat” in the 2025 Basic Policy on Economic and Fiscal Management and Reform (June 9, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (November 19, 2024)
- [Policy Recommendation] Integrating “Planetary Health” as a Growth Strategy — Proposal for the Grand Design and Action Plan for a New Form of Capitalism (2025 Revised Edition) (June 9, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
- [Policy Recommendations] HGPI Joint Input to the Zero Draft Political Declaration on NCDs and Mental Health (May 23, 2025)
Featured Posts
-
2025-07-04
[Registration Open] (Webinar) The 136th HGPI Seminar “Where We Are Now and Where We Are Going Regarding PPI in Mental Health Research: Learning from the TOGETHER Project in the Form of Co-Creation” (July 28, 2025)
-
2025-07-04
[Event Report] The HGPI Cardiovascular Disease (CVD) Control Promotion Project Online Global Symposium “Exploring the Future of CVD Control Through Policy Case Studies in the Asia-Pacific Region” (March 13, 2025)
-
2025-07-04
[HGPI Policy Column] (No. 62) From the Dementia Project “The Current State of Dementia Policy in the International Community in 2025”
-
2025-07-04
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-07-08
[Registration Open] Planetary Health Academy (Starts August 2025)